Physician profile
Eric H Leder
NPI 1134160898
$1,930.65
in general payments reported to CMS, 2019-2025
31 companies · $26.65 in 2025
The $26.65 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $483 · 2021: $530 · 2022: $516 · 2023: $81.31 · 2024: $154 · 2025: $26.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.92 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $173.41 | 2019-2024 | Airsupra, Breztri |
| Vanda Pharmaceuticals INC. | $162.08 | 2020-2021 | |
| Esperion Therapeutics, INC. | $155.04 | 2020-2022 | |
| Lilly USA, LLC | $153.40 | 2020-2022 | |
| Glaxosmithkline, LLC. | $148.29 | 2020-2024 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.22 | 2019-2022 | |
| Eisai INC. | $74.30 | 2020-2021 | |
| Amgen INC. | $57.56 | 2020-2024 | Prolia, Evenity, Repatha |
| Viiv Healthcare Company | $57.41 | 2022 | |
| Nestle Healthcare Nutrition INC. | $53.57 | 2021-2022 | |
| Novo Nordisk INC | $53.46 | 2022-2024 | Wegovy |
| Astellas Pharma US INC | $45.57 | 2020-2022 | |
| Pfizer INC. | $43.60 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.97 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.48 | 2021-2022 | |
| Allergan, INC. | $39.55 | 2020 | |
| Idorsia Pharmaceuticals US INC | $36.28 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $33.79 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.63 | 2022 | |
| Exact Sciences Corporation | $24.44 | 2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $23.73 | 2019 | |
| Dermira, INC. | $23.09 | 2020 | |
| Ibsa Pharma INC. | $19.50 | 2022 | |
| Gilead Sciences, INC. | $19.24 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $18.78 | 2022 | |
| Lucid Diagnostics INC. | $15.67 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.46 | 2020 | |
| Merck Sharp & Dohme LLC | $15.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.54 | 2022 | |
| Genentech USA, INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Leder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.